CMY-20, a novel AmpC-type β-lactamase from South African clinical Escherichia coli isolates

Diagnostic Microbiology and Infectious Disease

Volumn 60, Issue 4, 2008, Pages 405-408

  Mocktar, Chunderika ^a   Govinden, Usha ^a   Sturm, Adrian Willem ^b   Essack, Sabiha Yusuf ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

CMY 20; Escherichia coli; Plasmid mediated lactamase

Indexed keywords

BETA LACTAMASE AMPC; CMY 20; PLASMID DNA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SOUTH AFRICA;

AMINO ACID SUBSTITUTION; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CITROBACTER FREUNDII; DNA, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HOSPITALS; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIDS; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY, AMINO ACID; SOUTH AFRICA;

EID: 40749143540     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.11.009     Document Type: Article

References (19)

1. Bauernfeind A., Stemplinger I., Jungwirth R., and Giamarellou H. Characterization of the plasmidic β-lactamase CMY-2, which is responsible for cephamycin resistance. Antimicrob. Agents Chemother. 40 (1996) 221-224
2. Bush K., Jacoby G.A., and Medeiros A.A. A functional classification scheme and its correlation with molecular structure. Antimicrob. Agents Chemother. 39 (1995) 1211-1233
3. Decré D., Verdet C., Raskine L., Blanchard H., Burghoffer B., Philippon A., Sanson-Le-Pors M.J., Petit J.C., and Arlet G. Characterization of CMY-type β-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae in four hospitals in the Paris area. J. Antimicrob. Chemother. 50 (2002) 681-688
4. Doi Y., Shibata N., Shibayama K., Kamachi K., Kurokawa H., Yokoyama K., Yagi T., and Arakawa Y. Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 46 (2002) 2427-2434
5. Edelstein M., Pimkin M., Palagin I., Edelstein I., and Stratchounski L. Prevalence and molecular epidemiology of CTX-M extended spectrum β-lactamase production in Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob. Agents Chemother. 47 (2003) 3724-3732
6. Essack S.Y., Hall L.M.C., Pillay D.G., McFadyen M.L., and Livermore D.M. Complexity and diversity of Klebsiella pneumoniae strains with extended-spectrum β-lactamases isolated in 1994 and 1996 at a teaching hospital in Durban, South Africa. Antimicrob. Agents Chemother. 45 (2001) 88-95
7. Gazouli M., Kaufmann M.E., Tzelepi E., Dimopoulou H., Paniara O., and Tzouvelekis L. Study of an outbreak of cefoxitin-resistant Klebsiella pneumoniae in a general hospital. J. Clin. Microbiol. 35 (1997) 508-510
8. MOX-1 gene encoding AmpC-type β-lactamase. Gene 139 (1994) 93-98
9. Kado C.I., and Liu S.T. A rapid procedure for detection and isolation of large and small plasmids. J. Bacteriol. 145 (1981) 1365-1373
10. Koeck J.L., Arlet G., Philippon A., Basmaciogullari S., Thien H.V., Buisson Y., and Cavallo J.D. A plasmid-mediated CMY-2 β-lactamase from an Algerian clinical isolate of Salmonella senftenberg. FEMS Microbiol. Lett. 152 (1997) 255-260
11. 2 and pH on inhibition of TEM-1 and other β-lactamases by penicillanic acid sulfones. Antimicrob. Agents Chemother. 36 (1992) 1870-1876
12. Livermore D.M., and Williams J.D. Mode of action and mechanisms of bacterial resistance. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 4th ed. (1996), Williams and Wilkens 507-557
13. Miriagou V., Tzouvelekis L.S., Villa L., Lebessi E., Vatopoulos A.C., Carattoli A., and Tzelepi E. CMY-13, a novel inducible cephalosporinase encoded by an Escherichia coli plasmid. Antimicrob. Agents Chemother. 48 (2004) 3172-3174
14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed (2003), National Committee for Clinical Laboratory Standards, Wayne (PA)
15. Pérez-Pérez F.J., and Hanson N.D. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by multiplex PCR. J. Clin. Microbiol. 40 (2002) 2153-2167
16. Philippon A., Arlet G., and Jacoby G.A. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46 (2002) 1-11
17. Stapleton P.D., Shannon K.P., and French G.L. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactamase production and loss of an outer membrane protein. Antimicrob. Agents Chemother. 43 (1999) 1206-1210
18. Verdet C., Arlet G., Redjeb S.B., Hassen A.B., Lagrange P.H., and Philippon A. Characterization of CMY-4, an AmpC-type plasmid-mediated β-lactamase in a Tunisian clinical isolate of Proteus mirabilis. FEMS Microbiol. Lett. 169 (1998) 235-240
19. CMY genes in Escherichia coli and Salmonella isolates from food animals and ground meat. Antimicrob. Agents Chemother. 45 (2001) 3647-3650